- Title: Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative
   analysis of two protocols.
- 3

# 4 Running Title: Pooling samples to detect SARS-CoV-2 by RT-qPCR

- 5
- 6 VOLPATO, Fabiana<sup>a, b,c</sup>; LIMA-MORALES, Daiana<sup>a,c</sup>; WINK, Priscila Lamb<sup>a,c,d</sup>, WILLIG,
- 7 Julia <sup>c,e</sup>; PARIS, Fernanda<sup>c</sup>; ASHTON-PROLLA, Patricia<sup>f,e</sup>; BARTH, Afonso Luís<sup>a,b,c,d\*</sup>
- 8
- 9 a LABRESIS- Laboratório de Pesquisa em Resistência Bacteriana, Centro de Pesquisa
- 10 Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
- <sup>11</sup> <sup>b</sup> Programa de Pós-Graduação em Ciências Médicas (PPGCM), Faculdade de Medicina,
- 12 Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
- 13 ° Laboratório de Diagnóstico de SARS-CoV-2 (Lab Covid) Hospital de Clínicas de Porto
- 14 Alegre (HCPA), Porto Alegre, RS, Brazil
- <sup>15</sup> <sup>d</sup> Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF), Faculdade de
- 16 Farmácia, UFRGS, Porto Alegre, RS, Brazil
- <sup>17</sup> <sup>e</sup> Programa de Residência Multiprofissional do Hospital de Clínicas de Porto Alegre
- 18 (HCPA), Porto Alegre, RS, Brazil
- 19 <sup>f</sup> Departamento de Genética, UFRGS, Porto Alegre, RS, Brazil
- <sup>e</sup> Grupo de Pesquisa e Pós-Graduação e Pós Graduação, HCPA, Porto Alegre, RS, Brazil
- 21
- 22 \*Corresponding author: Afonso Luís Barth, LABRESIS- Laboratório de Pesquisa em
- 23 Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350,
- 24 Porto Alegre, RS, Brazil, 90.035-903. E-mail: albarth@hcpa.edu.br; Phone:
- 25 +555133598607.
- 26
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 27 Abstract

RT-qPCR for SARS-CoV-2 is the main diagnostic test used to identify the novel 28 29 coronavirus. Several countries have used large scale SARS-CoV-2 RT-gPCR testing as 30 one of the important strategies for combating the pandemic. In order to process the 31 massive needs for coronavirus testing, the usual throughput of routine clinical laboratories 32 has reached and often surpassed its limits and new approaches to cope with this 33 challenge must be developed. This study has aimed to evaluate the use pool of samples 34 as a strategy to optimize the diagnostic of SARS-CoV-2 by RT-qPCR in a general population. A total of 220 naso/orofaryngeal swab samples were collected and tested 35 36 using two different protocols of sample pooling. In the first protocol (Protocol A): 10 clinical 37 samples were pooled before RNA extraction. The second protocol (Protocol B) consisted 38 of pooling the already extracted RNAs from 10 individual samples. Results from Protocol A 39 were identical (100% agreement) with the individual results. However, for results from 40 Protocol B, reduced agreement (91%) was observed in relation to results obtained by 41 individual testing. Inconsistencies observed were related to RT-gPCR results with higher 42 Cycle Thresholds (Ct > 32.73). Furthermore, in pools containing more than one positive individual, the Ct of the pool was equivalent to the lowest Ct among the individual results. 43 44 These results provide additional evidence in favor of the clinical use of pooled samples for SARS-CoV-2 diagnosis by RT-qPCR and suggest that pooling of samples before RNA 45 extraction is preferrable in terms of diagnostic yield. 46

47

48 Key-words: Molecular Diagnostic, Pooling Sample, SARS-CoV-2, RT-qPCR, Massive
49 Testing.

# 50 Introduction

Due to the exponential increase of respiratory syndromes by SARS-CoV-2, the 51 52 World Health Organization (WHO) declared COVID-19 a pandemic of worldwide 53 importance (1). The rapid propagation of the virus significantly increases the demand on 54 the health care system. In response to the challenge of identifying and isolating infected 55 patients, in an attempt to minimize spread of the disease, two different types of tests have 56 been used: real time Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2 diagnosis mainly in upper respiratory tract samples and serum IgM and/or 57 IgG antibody detection assays to detect past infection and possibly immunity to the 58 59 disease.

In order to avoid diagnostic cross-reactivity with other endemic coronaviruses, most RT-qPCR assays include primers for at least two different molecular targets, such as nucleocapsid proteins 1 (N1) and 2 (N2) (2). A major advantage of real time assays is that amplification and analysis of the final product are performed simultaneously in a closed system. This procedure minimizes false-positive results associated with amplification of unspecific products (2).

Several countries have used RT-qPCR in large scale efforts as a mainstream 66 67 initiative for combating the SARS-CoV-2 pandemic. To enable massive coronavirus testing thousands of laboratories worldwide have expanded their routine and in several countries 68 69 high-troughput automated testing was implemented mainly in reference centers. However, many laboratories, especially in underserved areas became overloaded and new 70 71 approaches to cope with this ever increasing and long lasting challenge are needed, 72 especially in developing countries and if a strategy of massive testing, including 73 asymptomatic individuals is adopted. A few studies have provided encouraging results 74 that support the use of sample pooling as a robust and cost/time-saving approach in this

75 extreme scenario. In this brief report, we provide additional evidence in favor of SARS-

76 CoV-2 RT-qPCR analysis with pooled samples using two different methodologies.

77

### 78 Materials and Methods

Sample Pooling. A total of 220 samples from different patients were obtained by
 oro/nasopharyngeal swabbing performed by trained personnel in a single institution.

81 Individual swabs were mixed with 3mL of NaCl 0.9% solution. Two strategies of pooling

samples were evaluated: 1) Protocol A: consisted of 10 samples grouped (100µL from

83 each sample) before RNA extraction; 2) Protocol B: consisted of 10 samples group (4μL of

84 each) after the individual RNA extraction. Results from both protocols were compared to

individual analyses of the same samples, performed in parallel to the analysis of the pools.

86 RNA was extracted from all samples using the Abbott m2000sp automated system (Abbott

87 Laboratories, Chicago, USA) and the Abbott Sample Preparation System - 4x24 Preps

88 (Promega Corporation, Wisconsin, USA).

89 RT-qPCR Reaction. A previously validated SARS-CoV-2 RT-qPCR protocol following the 90 CDC guidelines and primers was used. In brief, Superscript III (SSIII) one step RT-qPCR 91 system (Thermo Fisher Scientific Inc, California, USA) was used for RT-gPCR reactions. 92 The master mix was composed of 5uL of 2X reaction buffer (0.4 mM of each dNTP and 6 93 mM MgSO<sub>4</sub>); 0.2µL of SuperScript<sup>™</sup> III RT/Platinum<sup>™</sup> Tag Mix; 0.2µL of ROX (dilution 1:10); 0.75µL of combined primers/probes mix of nCOV1 (N1 primer) or nCOV2 (N2 94 95 primer) or RP (2019-nCoV RUO Kit, IDT, Integrated DNA Technologies Inc, Iowa, USA) and 4µL of extracted RNA. The human ribonuclease P gene (RNAse P) was used as 96 97 internal control to monitor nucleic acid extraction, specimen quality and presence of 98 reaction inhibitors. Thermal cycling was performed at 50°C for 30 min for reverse 99 transcription, followed by 95 °C for 2 min and then 45 cycles of 95°C for 15s, 55 °C for 35s 100 in QuantStudio® 3 Applied Biosystems™ (Applied Biosystems, Massachusetts, USA). The

101 result was considered "negative" when neither N1 nor N2 targets amplified and "positive" 102 when both N1 and N2 targets amplified. RT-qPCR was considered "inconclusive" when 103 only one target (N1 or N2) amplified. Individual samples and pools with positive results had 104 the values of the Cycle Threshold (Ct) recorded. In order to analyze performance of the 105 assays with pooled samples, Ct values of individual and pooled sample runs were 106 compared.

To minimize inter-experiment variability ("batch effects") simultaneous analysis of the individual samples and their corresponding pools was undertaken in the same RTqPCR reaction. The 220 samples included in this study were sorted in 22 pools with 10 clinical samples each, for each protocol. The individual composition of the 22 pools for each protocol (A and B) was as follows: all negative samples (1/22), one inconclusive sample (1/22), only one positive sample (8/22), two positive samples (7/22), three positive samples (3/22), four positive samples (1/22), and five positive samples (1/22) (Table 1)

114

#### 115 **Results**

There was 100% and 91% of agreement when the results from individual and pooled samples with Protocol A (22 of 22) and Protocol B (20 of 22), respectively, were compared. The Cts of the individual samples with positive results ranged from 13.22 to 37.14, for both N1 and N2 targets. The Cts of the two individual samples with divergent results in Protocol B were >32.73 – Table 1. RNAse P used as a quality control presented very satisfactory results (Cts between 26 to 32).

122 It was possible to observe that Cts (both targets) of pooled samples in Protocol A 123 with positive results in the RT-qPCR tended to be 3 units higher in average when 124 compared to Cts of the individual tested positive samples (Table 1). This increase was 125 also observed in pools of the Protocol B for the N1 target but the Ct of N2 target presented 126 a difference of 4 units in average compared to the individually tested samples. Noteworthy,

in pools with more than one positive sample, Ct of the pool was similar to the lowest Ctobtained in the individual analyses of the samples included in the pool (Table 1).

129

#### 130 **Discussion**

A rapid and reliable laboratory diagnosis of SARS-CoV-2 infection plays a crucial 131 132 role for public health interventions related to the new coronavirus pandemic (3). RT-qPCR 133 detection of the virus by oro/nasopharyngeal swabbing is characterized by good sensitivity 134 and high specificity and has been regarded as the "gold standard" for the virus genome 135 detection (4). However, it is still a semi-automated strategy which includes several 136 sequential analytical steps and is associated with significant costs. Sample pooling is a 137 well known approach to optimize time and costs of massive screening strategies for 138 infectious diseases and has been reported as a reliable technique for Hepatitis B. Hepatitis 139 C and Human Immunodeficiency Virus in blood banks (5).

140 In this study, we demonstrate that RT-gPCR with primers for the nucleocapsid of SARS-CoV-2 using pooled samples (10/pool) is able to provide a correct diagnosis even 141 142 when only one individual sample is positive in the pool. In fact, the pool RT-gPCR analysis 143 identified a positive sample (Protocol A) even when the single sample analysis had a later 144 Ct (Ct > 32.73). As previously described, pools with a high number of samples (30 145 samples) may present false-negative results in the RT-qPCR for SARS-CoV-2 especially 146 when a positive sample has a later Ct (6). Therefore, according to our experience, we 147 suggest to make pools with a maximum of 10 samples/pool as this approach increases 148 significantly the diagnostic capacity of the labs without losing quality.

However, the size of the pool can accommodate different infection scenarios and it can be adequate if necessary, according to the institution necessity as suggested by Lohse et al (6). It has to be considered that the use of pools would present best

performance whether the population in analysis is expected to present low incidence of theCOVID-19 such as people without symptoms, for example.

The best performance of Protocol A in relation to Protocol B in our study is probably related to a larger volume of each individual clinical sample added to the pool (100µL of clinical sample). Furthermore, Protocol A is operationally straightforward and less time consuming as it requires only one RNA extraction. Moreover, the only pool which contained an individual sample with inconclusive result presented inconclusive result only using the Protocol A.

160 According to Buckingham et al (7), the absolute Ct comparison is only meaningful 161 when comparing experiments using the same reaction conditions. In this study, the individual and pooled samples were tested together in the same experimental run, and 162 163 using the same reagents. Considering the Ct differences between a positive individual sample and the same sample tested in a pool, we observed an average variation of 3 units 164 165 of Ct (Protocol A). According to the literature, using the same sample in a 10-fold dilution 166 series, the Ct values differ by ~3.3 units (7). These data corroborate with the Ct variation found in this study between the result of the RT-qPCR for SARS-CoV-2 of the individual 167 168 sample and of this sample in a pool with nine others. We also found that pools with more 169 than one positive sample present Cts more related to the lower Ct of the sample tested 170 individually.

Finally, the results of this study indicate that it is possible to obtain positive results of RT-qPCR for SARS-CoV2 when combining 10 clinical samples in one pool (Protocol A). The pooling of clinical samples would increase significantly test capacity of the laboratories. The use of pools would be much more effective to test clinical samples in scenarios of low prevalence of SARS-CoV-2 as a positive result of the pool will require that all samples be tested individually. In conclusion, to test populations in a large scale, the use of pools is a very useful strategy as an epidemiological screening method.

# 178 Acknowledgments

- 179 This study received a grant of "Fundação de Apoio a Pesquisa e Ensino do rio
- 180 Grande do Sul (FAPERGS)" (#20-2551-0000265-9) as well as of "Fundo de Incentivo a
- 181 Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE/HCPA) (#2020-
- 182 **0163**).

## 184 **References**

- 185 1. Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J, Veit
- 186 M, Su S. 2020. COVID-19: Epidemiology, Evolution, and Cross-Disciplinary
- 187 Perspectives. Trends Mol Med 26:483-495.
- 188 https://doi.org/10.1016/j.molmed.2020.02.008
- 189 2. Tang YW, Schmitz JE, Persing DH, Stratton CW. 2020. Laboratory Diagnosis of
- 190 COVID-19: Current Issues and Challenges. J Clin Microbiol 58:e00512-20.
- 191 https://doi.org/10 .1128/JCM.00512-20
- 192 3. Lu X, Whitaker B, Sakthivel SKK, Kamili S, Rose LE, Lowe L, Mohareb E, Elassal
- 193 EM, Al-sanouri T, Haddadin A, Erdman DD. 2014. Real-Time Reverse
- 194 Transcription-PCR assay panel for Middle East Respiratory Syndrome Coronavirus.

195 J Clin Microbiol 52(1):67-75. https://doi.org/10.1128/JCM.02533-13

- 4. Shen M, Zhou Y, Ye J, Al-maskri AAA, Kang Y, Zeng S, Cai S. 2020. Recent
- 197 advances and perspectives of nucleic acid detection for coronavirus. J Pharm Anal

198 10:97-101. https://doi.org/10.1016/j.jpha.2020.02.010

199 5. Nguyen T, Bang D D, Wolff A. 2020. 2019 Novel Coronavirus Disease (COVID-19):

200 Paving the road for rapid detection and Point-of-Care diagnostics. Micromachines

- 201 11. https://doi.org/10.3390/mi11030306
- Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geiβler T, Gärtner B. 2020. Pooling of
   samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis.
   https://doi.org/10.1016/S1473.2009(20)20262.5
- 204 https://doi.org/10.1016/ S1473-3099(20)30362-5
- 205 7. Buckingham L. 2019. Chapter 6: Nucleic Acid Amplification, p 142-178. *In*
- 206 Buckingham L. Molecular Diagnostics: Fundamentals, Methods, and Clinical
- 207 Applications, 3th ed, F.A. Davis Company.

## 208 **Table 1:** Cycle Threshold results of pooling samples for detection of SARS-CoV-2 by RT-qPCR.

Pool Identification	Protocol A* Ct N1	Protocol A Ct N2	Protocol B** Ct N1	Protocol B Ct N2	Number of positive samples in the pool	Value of lower Ct positive in the pool N1	Value of lower Ct positive in the pool N2
POOL 1	Negative	Negative	Negative	Negative	0	-	-
POOL 2	35.44	38.46	Negative	Negative	1	32.73	35.05
POOL 3	22.02	22.64	22.26	22.99	2	19.02	19.96
POOL 4	16.66	16.82	16.84	16.78	1	13.54	13.22
POOL 5	20.57	20.98	20.96	21.25	1	17.39	17.85
POOL 6	Negative	27.72	Negative	Negative	Inconclusive	Negative	37.14
POOL 7	24.13	25.31	27.36	29.06	1	20.37	20.23
POOL 8	35.41	38.97	Negative	38.42	1	33,79	36.28
POOL 9	19.35	21.18	19.81	21.53	2	16.06	17.39
POOL 10	21.04	21.94	20.69	20.59	2	18.17	18.82
POOL 11	21.61	23.29	21.48	23.42	5	19.12	18.91
POOL 12	31.21	33.27	30.41	33.23	2	27.07	29.23
POOL 13	20.54	20.32	24.48	25.12	4	20.89	20.55
POOL 14	24.08	27.24	20.79	22.36	3	18.23	19.39
POOL 15	17.00	18.21	16.97	18.18	3	13.55	15.01
POOL 16	28.89	31.42	28.81	31.23	2	25.47	27.17
POOL 17	20.50	21.41	20.96	21.96	3	17.97	18.74
POOL 18	27.57	29.11	26.54	28.7	2	24.05	25.12
POOL 19	21.34	22.06	21.41	22.40	1	18.13	18.59
POOL 20	32.61	34.17	32.54	39.07	1	29.33	30.51
POOL 21	28.02	29.26	26.99	27.26	2	23.68	24.26
POOL 22	19.23	19.73	19.31	19.76	1	16.11	16.74

<sup>209</sup> \*Protocol A: Pooling of clinical samples prior to perform RNA extraction.

210 \*\*Protocol B: Pooling samples after individual RNA extraction.